Pcv13

Adult female C57/Bl6 mice housed as above, were vaccinated intrapareteneally with 1:50 human dose (10μL vaccine+90μL PBS) PCV-13 (Pfizer) or 10μg recombinant protein: rCppA, or rPiaA, (prepared as described below) conjugated to 130μg alum, or 130μg Alum in a volume of 100μL PBS two weeks prior to mating and then boosted every two weeks for the duration of the study. Pups were infected with wild type BHN97 and monitored as above. For analysis of circulating antibody response by western and ELISA, two additional adult male mice were vaccinated with each antigen and boosted twice. One week following the final boost the mice were anesthetized with 4% isoflorane and bleed by retro-orbital route and maximum blood volume was collected. Mice were then euthanized by CO₂ asphyxiation followed by cervical dislocation.

Our analysis was performed from the societal perspective, including both medical and nonmedical costs. Medical costs were from MarketScan data [35 ] while nonmedical costs were informed from Ray et al. [36 (link)] and a Morbidity and Mortality Weekly Report [37 (link)]. For medical costs, conversions to 2021 dollars were done using the Consumer Price Index for medical care. For nonmedical costs, conversions to 2021 dollars were done using the Consumer Price Index for all items [38 ]. All outcomes were discounted by 3% annually. The public ($150.83) and private ($226.43) prices of a dose of PCV13 were obtained from CDC’s 2021 vaccine price list [39 ] and were weighted by public (61%) and private (39%) purchase shares from Pfizer’s (manufacturer of PCV13) internal sales data for 2021 (obtained through email communication). We assumed a vaccine administration cost of $15.04 [40 (link)] and travel/caregiver time cost as $33.30 [41 (link)]. At the time of this analysis, PCV15 (manufactured by Merck) did not have a published price for use within the pediatric population. Based on the price of PCV15 use among adults and following discussions Merck, we assumed the private price for PCV15 was $216.09 and the public price was $150.83.

Our analysis was performed from the societal perspective, including both medical and nonmedical costs. Medical costs were from MarketScan data [35 ] while nonmedical costs were informed from Ray et al. [36 (link)] and a Morbidity and Mortality Weekly Report [37 (link)]. For medical costs, conversions to 2021 dollars were done using the Consumer Price Index for medical care. For nonmedical costs, conversions to 2021 dollars were done using the Consumer Price Index for all items [38 ]. All outcomes were discounted by 3% annually. The public ($150.83) and private ($226.43) prices of a dose of PCV13 were obtained from CDC’s 2021 vaccine price list [39 ] and were weighted by public (61%) and private (39%) purchase shares from Pfizer’s (manufacturer of PCV13) internal sales data for 2021 (obtained through email communication). We assumed a vaccine administration cost of $15.04 [40 (link)] and travel/caregiver time cost as $33.30 [41 (link)]. At the time of this analysis, PCV15 (manufactured by Merck) did not have a published price for use within the pediatric population. Based on the price of PCV15 use among adults and following discussions Merck, we assumed the private price for PCV15 was $216.09 and the public price was $150.83.